CSBR Stock Slips Post Q1 Earnings Despite Revenue, Margin Growth

Champions Oncology (CSBR) reported Q1 FY2027 revenues of $15.2 million, up 8.8% year-over-year, with improved margins and narrowed losses. However, the stock declined 1.8% post-earnings. The company saw strong growth in data-license revenues (up 187.1%) but faced headwinds from declining Other TOS revenues. Management emphasized continued investment in sales and marketing while pursuing funding or licensing partnerships for its Corellia platform.